Skip to main content

Table 1 Clinicopathological characteristics of the breast cancer patient cohort

From: Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

Parameter Randomized
untreated
(n=232)
Tamoxifen
(n=212)
Total
(n=444)
Age at diagnosis (year)
 Median 45.00 45.00 45.00
 Range 26–57 25–57 25–57
Follow-up time without death from breast cancer
 Median 28.09 28.56 28.41
 10th percentile 20.48 21.35 20.56
 90th percentile 30.85 30.72 30.74
Tumor size (mm)
 Median 23.00 25.00 24.00
 Range 2–50 8–75 2–75
Tumor histology
 Ductal 194 176 370
 Lobular 18 17 35
 Medullar 13 9 22
 Missing: 17    
Tumor grade
 Grade 1 31 23 54
 Grade 2 100 86 186
 Grade 3 96 92 188
 Missing: 16    
Lymph node (LN) status
 LN Positive 166 144 310
 LN Negative 65 67 132
 Missing: 2    
Estrogen receptor (ERα)
 ERα positive 173 144 317
 ERα negative 47 49 96
 Missing: 31    
Progesterone receptor (PR)
 PR positive 122 108 230
 PR negative 63 61 124
 Missing: 90    
Human epidermal growth factor receptor 2 (HER2)
 HER2 negative 186 172 358
 HER2 positive 35 25 60
 Missing: 26
Progranulin expression
 High 66 73 139
 Low 149 124 273
 Missing: 32    
Sortilin expression
 High 116 109 225
 Low 107 95 202
 Missing: 17    
\